N. Yuldasheva

发表

Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine

Lawrence Tamarkin, S. Libutti, M. Walker, 2010, Clinical Cancer Research.

Results of a completed phase I clinical trial of CYT-6091: A pegylated colloidal gold-TNF nanomedicine.

S. Libutti, M. Walker, G. Paciotti, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CLINICAL, GENETIC AND RADIOGRAPHIC ANALYSIS OF 108 PATIENTS WITH VON HIPPEL-LINDAU DISEASE (vHL) MANIFESTED BY PANCREATIC NEUROENDOCRINE TUMORS (PNETs)

P. Choyke, W. Linehan, H. Alexander, 2019 .

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).

Peter L Choyke, W Marston Linehan, S. Libutti, 2007, Surgery.

Preliminary results of a phase I clinical trial of CYT-6091: A pegylated colloidal gold-TNF nanomedicine

S. Libutti, G. Paciotti, L. Myer, 2007 .

A randomized phase II trial comparing two doses of lenalidomide for the treatment of stage IV ocular melanoma.

S. Libutti, G. Seidel, N. Yuldasheva, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.